Ge Long Hui A P P·2026-01-12 12:06Group 1 - The core viewpoint of the article is that Wanbangde Pharmaceutical Group has entered into a strategic partnership with Zhejiang Haixiang Pharmaceutical to advance the development and commercialization of the WP205 product, aimed at treating amyotrophic lateral sclerosis (ALS) [1] - The collaboration is formalized through an "Innovative Drug Cooperation Agreement" signed on January 12, 2026, focusing on leveraging each company's strengths for mutual development and strategic win-win outcomes [1] - The initial phase of the partnership will concentrate on the research and commercialization of the WP205 product, which has already received orphan drug designation, with a total investment of 150 million RMB [1] Group 2 - The agreement also includes future collaboration on small molecule cyclic peptide agonists targeting melanocortin receptors (MCR), covering aspects such as raw materials and formulations [1]